INTRODUCTION {#s1}
============

Although kidney transplant (KT) recipients have demonstrated improved survival compared with patients undergoing dialysis, cardiovascular (CV) mortality is the leading cause of death following KT, accounting for 40--55% of all deaths \[[@R1], [@R2]\]. Identifying patients who are at high risk for CV disease could be important for offering appropriate management before KT.

Several baseline echocardiographic abnormalities have been found to have prognostic significance in patients with ESRD \[[@R3]--[@R5]\], but only limited data on echocardiographic prognostic factors are available in KT recipients \[[@R6]--[@R9]\]. Especially, there has been a lack of relevant research of the effect of pre-KT LVDD and left atrial enlargement (LAE) on posttransplant acute coronary syndrome (ACS).

In the general population, an increase in left atrial volume index (LAVI) and E wave over tissue-Doppler imaging of the E wave (E/E') ratio is associated with elevated left ventricular (LV) filling pressures and significant diastolic dysfunction \[[@R10]\]. In KT recipients, there have been observed a significant reduction in left ventricular diastolic dysfunction (LVDD) rates after KT, and it may be caused by resolved occult volume overload \[[@R11], [@R12]\]. Despite the potential benefits of KT on cardiac function, one study suggested that pre-KT left ventricular hypertrophy (LVH), ventricular dilatation, and systolic dysfunction were associated with higher all-cause mortality and CV mortality after KT \[[@R7]\]. In another study, age, LV end-systolic diameter, maximal wall thickness, and mitral annular calcification were proposed as independent predictors of mortality after KT \[[@R8]\].

The 2012 AHA Scientific Statement recommended considering noninvasive stress testing in KT candidates with no active cardiac conditions, based on the presence of multiple CAD risk factors \[[@R13]\]. Non-stress echocardiography has been routinely conducted in Korea for assessing baseline heart function before KT. In contrast, non-invasive stress tests were not widely performed in KT candidates before 2012.

The aim of this study was to identify the prognostic effect of pretransplant conventional echocardiographic findings with LVDD and LAE for predicting outcomes of acute coronary syndrome (ACS) and mortality in KT recipients.

RESULTS {#s2}
=======

Baseline data by LVDD and outcomes {#s2_1}
----------------------------------

The baseline characteristics of 2779 enrolled patients are described in Table [1](#T1){ref-type="table"}. In higher-grade LVDD, age at transplantation was younger and the proportion of men and smokers was higher. The mean age of patients at KT was 41.7 years, and 59.6% were men. During a mean follow-up of 4.5 years, non-fatal ACS and composite of fatal/non-fatal ACS occurred in 49 (1.8%) and 89 (3.2%) patients respectively, and 116 (6.2%) died.

###### Baseline characteristics of the study subjects

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             Total\          LVDD grade--based group   *P*-value       Total\         LA size--based group   *P*-value                                                       
                                             (*N* = 2779)                                              (*N* = 2727)                                                                                          
  ------------------------------------------ --------------- ------------------------- --------------- -------------- ---------------------- --------------- --------------- --------------- --------------- -------------
  Age at transplantation (years)^a^          41.7 ± 11.6     41.9 ± 11.7               40.5 ± 10.8     0.05           42.0 ± 11.3            39.0 ± 11.0     41.6 ± 10.9     43.6 ± 11.2     44.5 ± 11.3     \< 0.001^d^

  Recipient's sex (male, %)                  59.6            58.0                      72.9            \< 0.001       59.4                   46.6            57.0            63.5            73.6            \< 0.001

  BMI (kg/m^2^)^a^                           22.9 ± 11.6     23.0 ± 12.2               22.5 ± 2.9      0.51           23.0 ± 11.7            21.8 ± 10.2     23.2 ± 13.5     23.1 ± 8.2      24.0 ± 13.6     0.008^e^

  Current smoker (%)                         9.5             9.0                       14.6            \< 0.001       9.6                    6.0             8.8             11.0            13.3            \< 0.001

  Comorbidities (%)                                                                                                                                                                                          

   Hypertension                              82.4            82.1                      85.4            0.19           82.8                   75.9            81.5            87.7            88.0            \< 0.001

   Diabetes mellitus                         19.3            18.8                      23.6            0.06           19.6                   12.7            18.3            24.1            25.0            \< 0.001

   Vascular disease^b^                       6.2             6.0                       7.6             0.30           6.2                    4.3             6.1             6.4             8.5             0.01

   Dyslipidemia                              55.3            53.9                      71.8            0.04           57.3                   54.0            59.7            53.7            61.6            0.52

  Dialysis before KT                         83.8            83.6                      86.6            0.63           83.7                   82.7            82.7            84.2            85.5            0.77

   HD                                        56.0            56.2                      55.4                           56.5                   55.5            56.5            58.4            55.5            

   PD                                        24.3            23.9                      27.9                           23.9                   23.4            23.5            22.9            25.9            

   Modality conversion (HD→PD or PD→HD)      3.5             3.5                       3.3                            3.3                    3.8             2.7             2.9             4.1             

  Recipient CMV IgG (+) (%)                  57.3            57.6                      54.9            0.38           58.2                   61.3            58.7            58.8            53.5            0.03

  Dialysis duration (months)^a^              33.2 ± 40.2     34.3 ± 13.2               31.3 ± 37.2     0.38           33.0 ± 40.3            31.4 ± 38.1     34.0 ± 42.5     31.2 ± 39.2     41.3 ± 1.7      0.16

  Intact PTH (pg/mL)                         229.6 ± 252.6   228.9 ± 246.6             236.0 ± 305.0   0.90           229.0 ± 255.3          277.9 ± 351.5   192.4 ± 166.0   263.3 ± 284.1   188.9 ± 181.0   0.15

  Donor's age (years)^a^                     39.3 ± 12.1     39.4 ± 12.2               38.2 ± 11.3     0.27           39.2 ± 12.1            39.6 ± 12.6     39.5 ± 11.8     38.9 ± 12.3     38.7 ± 11.8     0.44

  Donor's sex (male, %)                      58.0            57.9                      59.0            0.75           58.2                   60.6            55.7            57.2            59.3            0.26

  Deceased donor (%)                         24.3            24.7                      20.8            0.19           23.9                   23.4            23.8            21.5            26.8            0.17

  Donor CMV IgG (+) (%)                      60.3            60.6                      57.3            0.28           61.1                   62.7            58.9            64.9            58.2            0.04

  Steroid maintenance strategy (%)           91.8            91.3                      97.0            0.50           91.8                   92.6            90.9            89.6            95.4            0.58

  CNI (CsA:Tacrolimus, %)                    50.7:49.0       50.2:49.4                 54.5:45.5       0.49           50.8:48.9              48.8:50.6       49.7:50.2       51.2:48.8       54.3:45.5       0.29

  Antimetabolites (Aza:MMF, %)               19.9:77.0       19.2:77.5                 26.3:72.8       0.03           20.1:76.9              19.9:77.9       19.0:75.8       19.3:78.5       22.3:75.4       0.01

  CMV disease (%)                            5.7             5.8                       4.5             0.54           5.7                    7.2             5.2             5.3             5.0             0.36

  Pretransplant echocardiographic findings                                                                                                                                                                   

   LA size (mm)^a^                           39.2 ± 6.3      38.2 ± 5.7                47.2 ± 5.2      \< 0.001       39.2 ± 6.3             31.8 ± 2.9      37.6 ± 1.1      41.3 ± 1.1      47.6 ± 3.5      \< 0.001^f^

   Grades 2--3 LVDD (%)                      ---             ---                       ---             ---            10.5                   0.9             1.2             5.4             37.5            \< 0.001

   LVIDs (mm)^a^                             33.1 ± 6.1      32.6 ± 5.7                37.7 ± 7.3      \< 0.001       33.1 ± 6.1             31.8 ± 2.9      37.6 ± 1.1      41.3 ± 1.1      47.6 ± 3.5      \< 0.001^f^

   LVIDd (mm)^a^                             51.8 ± 6.2      51.2 ± 5.9                56.8 ± 6.2      \< 0.001       51.8 ± 6.2             48.1 ± 5.2      51.2 ± 4.9      52.8 ± 5.2      56.2 ± 6.3      \< 0.001^f^

   IVSd (mm)^a^                              10.7 ± 2.1      10.6 ± 2.1                11.9 ± 2.1      \< 0.001       10.7 ± 2.1             9.6 ± 1.8       10.5 ± 1.7      11.1 ± 2.0      12.1 ± 2.1      \< 0.001^f^

   LV ejection fraction (EF, mean of %)^a^   60.4 ± 7.4      60.7 ± 7.0                57.6 ± 10.0     \< 0.001       60.4 ± 7.4             60.8 ± 6.5      61.3 ± 6.4      60.9 ± 6.7      58.2 ± 9.5      \< 0.001^g^

   LVEF \< 50% (%)                           6.9             5.6                       18.2            \< 0.001       6.8                    4.4             4.5             5.3             13.9            \<0.001

   LV mass index (g/m^2^)                    121.6 ± 35.9    118.0 ± 34.3              155.0 ± 32.9    \< 0.001       124.0 ± 34.4           100.4 ± 25.8    124.6 ± 38.6    127.5 ± 29.6    152.7 ± 35.8    \< 0.001^i^

   Severe LVH (%)^c^                         65.9            63.1                      90.3            \< 0.001       66.9                   39.2            67.4            76.2            89.9            \< 0.001

   E/A ratio^a^                              1.08 ± 0.42     1.02 ± 0.36               1.57 ± 0.59     \< 0.001       1.08 ± 0.42            1.10± 0.39      1.05 ± 0.36     1.02 ± 0.36     1.14 ± 0.53     \< 0.001^i^

   E/E'^a^                                   12.4 ± 5.0      11.4 ± 4.0                18.9 ± 6.1      \< 0.001       12.4 ± 5.0             9.8 ± 3.3       11.7 ± 3.9      12.6 ± 4.1      16.2 ± 6.2      \< 0.001^i^

   MVDT (msec)^a^                            208 ± 61        210 ± 61                  191 ± 61        0.06           212 ± 59               205 ± 62        206 ± 48        213 ± 53        224 ± 71        0.06

   Systolic PAP (mmHg)^a^                    29.9 ± 8.7      28.6 ± 6.8                39.4 ± 13.2     \< 0.001       29.9 ± 8.6             26.1 ± 5.0      28.0 ± 5.6      30.1 ± 8.5      35.6 ± 11.0     \< 0.001^f^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Data are expressed as the mean ± SD.

^b^Vascular disease included cardiovascular, cerebrovascular, and peripheral vessel diseases.

^c^Severe LVH was defined as LVMI of \> 120 g/m^2^ for women and \> 150 g/m^2^ for men.

LVM (g) = 1.05\[(LVEDD + IVS + PW)^3^ − LVEDD^3^\]

LVMI (g/m^2^) = Left ventricular mass/body surface area

^d^*P* \< 0.05 at post-hoc analysis between all the groups except for group 3 and 4.

^e^*P* \< 0.05 at post-hoc analysis between group 1 and 4.

^f^*P* \< 0.05 at post-hoc analysis between all the groups.

^g^*P* \< 0.05 at post-hoc analysis between the each of group 1, 2, 3 and group 4.

^h^*P* \< 0.05 at post-hoc analysis between group 1 and 3, 2 and 4, and 3 and 4.

^i^*P* \< 0.05 at post-hoc analysis between all the groups except for group 2 and 3.

LVDD: left ventricular diastolic dysfunction; LA: left atrium; BMI: body mass index; KT: kidney transplantation; HD: hemodialysis; PD: peritoneal dialysis; CMV IgG: cytomegalovirus immunoglobulin G; PTH: parathyroid hormone; CNI: calcineurin inhibitor; CsA: cyclosporine A; Aza: azathioprine; MMF: mycophenolate mofetil; LVIDs: left ventricular internal dimension in systole; LVIDd: left ventricular internal dimension in diastole; IVSd: interventricular septum in diastole; LVH: left ventricular hypertrophy; MVDT: mitral valve deceleration time; PAP: pulmonary artery pressure.

Comorbidities, dialysis and donor factors did not differ between the two groups. Preemptive KT was performed in 16.2% of patients, and hemodialysis was performed before KT in 55% of patients. Higher-grade LVDD was associated with more cases of dilated LA, LV, and decreased LV systolic function.

ACS occurred significantly more often in the group diagnosed with LVDD grades 2--3 (*P* = 0.005 for non-fatal ACS, *P* = 0.02 for fatal/non-fatal ACS). No meaningful difference was seen in all-cause mortality (*P* = 0.50) (Figure [1](#F1){ref-type="fig"}).

![Kaplan--Meier curves for posttransplant occurrence of ACS and all-cause mortality in the LVDD grade--based group\
(**A, B**) Patients with LVDD grades 2--3 showed worse ACS outcomes than the patient group with LVDD grades 0--1 (*P* = 0.005 for non-fatal, *P* = 0.02 for fatal/non-fatal ACS). (**C**) All-cause mortality did not differ between the two groups (*P* = 0.50).](oncotarget-08-71154-g001){#F1}

Baseline data by LAE and outcomes {#s2_2}
---------------------------------

The baseline characteristics of 2727 patients are described in Table [1](#T1){ref-type="table"}. Larger size LA was associated with more dilated LV, LVH, and decreased LV systolic function than smaller size LA (Table [1](#T1){ref-type="table"}).

When we analyzed patients by LA size, ACS occurred more frequently in the subgroup with larger LA size, similar to previous results (*P* = 0.001 for non-fatal ACS, *P* = 0.03 for fatal/non-fatal ACS). No meaningful difference was seen in all-cause mortality (*P* = 0.50), as in the LVDD group (Figure [2](#F2){ref-type="fig"}). The patients who experienced non-fatal ACS showed increased all-cause mortality than others especially after 5 years of KT (*P* \< 0.001, Figure [3](#F3){ref-type="fig"}).

![Kaplan--Meier curves for post-KT occurrence of ACS and all-cause mortality in the LA size--based group\
(**A, B**) Patients with larger LA size showed worse ACS outcomes than patients with smaller LA size (*P* = 0.001 for non-fatal, *P* = 0.03 for fatal/non-fatal ACS). (**C**) All-cause mortality did not differ between the two groups (*P* = 0.50).](oncotarget-08-71154-g002){#F2}

![Kaplan--Meier curve for all-cause mortality by non-fatal ACS after KT (*P* \< 0.001)](oncotarget-08-71154-g003){#F3}

Subgroup analysis of LVDD and LAE {#s2_3}
---------------------------------

In the patients who had both LVDD grades 2--3 and LAE, ACS occurred significantly more often than others (*P* \< 0.001 for non-fatal ACS, *P* = 0.01 for fatal/non-fatal ACS). The result for mortality (*P* = 0.62) was statistically insignificant overall (Figure [4](#F4){ref-type="fig"}), though the mortality was higher in patients who had both LVDD grades 2--3 and LAE, specifically in the population who was followed up for \> 5 years (*P* = 0.008, data not shown).

![Kaplan--Meier curves for post-KT occurrence of ACS, GF, and all-cause mortality in the LVDD grade-- and median LA size based groups\
(**A, B**) In patients who had both LVDD grades 2--3 and LAE, ACS occurred significantly more often than in patients who were diagnosed with LVDD or LAE alone (*P* = 0.001 for non-fatal ACS, *P* = 0.01 for fatal/non-fatal ACS). (**C**) Results for all-cause mortality were statistically insignificant overall (*P* = 0.62).](oncotarget-08-71154-g004){#F4}

We further analyzed the outcomes by comparing preemptive KT and long-term dialysis before KT. In patients who underwent preemptive KT, ACS and mortality did not differ according to LVDD and LA size based groups, but in patients who underwent long-term dialysis before KT, occurrences of non-fatal ACS (*P* = 0.001) and fatal/non-fatal ACS (*P* = 0.005) were significantly higher in LVDD grades 2--3 group ([Supplementary Figures 1 and 2](#SD1){ref-type="supplementary-material"}). When we analyzed patients who underwent long-term dialysis before KT, a diagnosis of LVDD grades 2--3 was associated with a higher incidence of non-fatal ACS (*P* = 0.006) and fatal/non-fatal ACS (*P* = 0.005) only in patients who underwent hemodialysis before KT. All-cause mortality (*P* = 0.08) did not show significant differences between groups according to dialysis modality ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}).

In aspects of concomitant LV systolic dysfunction, non-fatal ACS occurred more in patients who had both LVDD grades 2--3 and LAE (*P* = 0.001) when LVEF was ≥ 50%. None of the outcomes were significantly different by the LVDD grades-based groups, LA size-based groups, or LVDD and LA composite groups in LVEF \< 50% (data not shown).

Factors affecting the occurrence of ACS {#s2_4}
---------------------------------------

We conducted multivariate analysis for the occurrence of ACS (Table [2](#T2){ref-type="table"}). When we adjusted for age, sex, hypertension, DM, dyslipidemia, smoking, previous history of IHD or previous history of vascular disease, and aortic regurgitation (AR), we found that increased age (*P* = 0.001), hypertension (*P* = 0.04), DM (*P* = 0.02), previous history of CV events (*P* = 0.001), and LVDD grades 2--3 (HR 2.980, 95% CI 1.535--5.787; *P* = 0.001) were associated with non-fatal ACS in KT recipients. When we analyzed the LAE size, after adjusting for the same variables (except for LVDD grade), we also found a significantly higher incidence of ACS (HR 1.052, 95% CI 1.006--1.101; *P* = 0.03)(Table [2](#T2){ref-type="table"}). In these models, LVDD grades 2--3 were associated with a threefold increased relative risk of non-fatal ACS, and a 1-mm increase in LA size was associated with a 5.2% increase in relative risk of non-fatal ACS (*P* = 0.001). However, neither LVDD nor LAE was significantly associated with all-cause mortality in a multivariate analysis.

###### Factors associated with the occurrence of fatal/non-fatal ACS after KT

                                           Non-fatal ACS   Fatal/non-fatal ACS                                                                                                           
  ---------------------------------------- --------------- --------------------- ---------- ------- --------------- ---------- ------- --------------- ---------- ------- -------------- ----------
  Age (per year)                           1.097           1.066--1.129          \< 0.001   1.099   1.063--1.135    \< 0.001   1.058   1.038--1.079    \< 0.001   1.054   1.032--1.077   \< 0.001
  Female                                   0.527           0.278--0.998          0.05       1.196   0.619--2.314    0.59       0.599   0.377--0.952    0.03       1.288   0.806--2.057   0.29
  Hypertension                             10.422          1.435--75.686         0.02       7.747   1.057--56.807   0.04       2.199   1.057--4.577    0.04       1.839   0.879--3.849   0.11
  Diabetes mellitus                        5.342           3.018--9.457          \< 0.001   2.199   1.156--4.183    0.02       3.117   2.022--4.803    \< 0.001   1.889   1.171--3.048   0.009
  Dyslipidemia                             2.155           0.756--6.141          0.15       1.058   1.002--1.117    0.83       1.525   0.598--3.890    0.38       0.972   0.373--2.532   0.95
  Smoking                                  1.878           0.871--4.048          0.11       1.125   0.511--2.476    0.77       1.209   0.618--2.363    0.58       0.834   0.424--1.640   0.60
  Previous history of IHD                  11.095          5.776--21.310         \< 0.001   5.323   2.130--13.301   \< 0.001   6.668   3.778--11.766   \< 0.001   4.312   2.445--7.604   \< 0.001
  Previous history of vascular disease     8.000           4.310--14.850         \< 0.001   3.256   1.712--6.583    \< 0.001   5.193   3.099--8.700    \< 0.001   2.900   1.675--5.022   \< 0.001
  Donor sex (female)                       1.220           0.685--2.175          0.50       ---     ---             ---        0.883   0.570--1.368    0.58       ---     ---            ---
  Donor age                                1.001           0.995--1.007          0.79       ---     ---             ---        1.000   0.994--1.006    0.99       ---     ---            ---
  HD                                       1.853           0.641--5.353          0.26       ---     ---             ---        1.158   0.545--2.459    0.70       ---     ---            ---
  Deceased donor                           1.683           0.850--3.333          0.14       ---     ---             ---        1.463   0.881--2.431    0.14       ---     ---            ---
  NODAT                                    1.804           0.805--4.041          0.15       ---     ---             ---        2.663   1.331--5.330    0.006      2.033   0.936--4.416   0.07
  Intact PTH                               1.000           0.997--1.003          0.94       ---     ---             ---        1.000   0.997--1.003    0.94       ---     ---            ---
  LA diameter (per 1 mm)^a^                1.101           1.056--1.148          \< 0.001   1.052   1.006--1.101    0.03       1.064   1.030--1.099    \< 0.001   1.033   1.002--1.068   0.05
  LV ejection fraction                     0.996           0.959--1.033          0.82       ---     ---             ---        0.989   0.963--1.016    0.42       ---     ---            ---
  Diastolic dysfunction (grades 2--3)^a^   2.882           1.486--5.593          0.002      2.980   1.535--5.787    0.001      2.108   1.224--3.628    0.007      1.908   1.122--3.246   0.02
  Valvular disease                                                                                                                                                                       
  MR (grade 3)                             2.365           0.308--18.188         0.41       ---     ---             ---        2.935   0.668--12.901   0.15       ---     ---            ---
  TR (grade 3)                             3.526           0.433--28.715         0.24       ---     ---             ---        2.200   0.275--17.600   0.46       ---     ---            ---
  AR (grade 2)                             5.671           1.279--25.150         0.02       3.570   0.831--15.331   0.09       3.139   0.718--13.729   0.13       2.052   0.492--8.536   0.32
  CMV disease after transplantation        1.864           0.557--6.238          0.31       ---     ---             ---        1.090   0.389--3.052    0.87       ---     ---            ---

Data were analyzed by using the Cox regression, Enter method in the multivariate analysis.

^a^Age, sex, hypertension, DM, dyslipidemia, smoking, previous history of IHD, and AR were used as covariates with one of LA diameter or diastolic dysfunction.

IHD: ischaemic heart disease; HD: hemodialysis; NODAT: new-onset diabetes after transplant; LA: left atrium; LV: left ventricle; MR: mitral regurgitation; TR: tricuspid regurgitation; AR: aortic regurgitation; CMV: cytomegalovirus.

Incrementally, the predictive values of LVDD and LA size showed significantly superior powers of discrimination for ACS (Table [3](#T3){ref-type="table"}). After adjusting for traditional risk factors, such as age, hypertension, DM, and smoking, including LVDD increased area under the receiver operating characteristic (ROC) curve (AUC) from 0.721 to 0.762 (*P* = 0.04) for predicting non-fatal ACS occurrence. The net reclassification improvement (NRI) and integrated discrimination improvement (IDI) also showed significant improvements in discrimination (NRI = 0.486; *P* = 0.001, IDI = 0.009; *P* = 0.02). LA size showed a similar, but less significant improvement (NRI = 0.346; *P* = 0.02, IDI = 0.008; *P* = 0.02)(Table [3](#T3){ref-type="table"}).

###### Incremental value of LVDD or LA size over traditional risk factors for predicting ACS after KT

                                AUC     Category-free NRI   IDI                        
  ----------------------------- ------- ------------------- ------- ---------- ------- ------
  Traditional risk factors^a^   0.721   ---                 ---     ---        ---     ---
   + LVDD                       0.762   0.04                0.486   \< 0.001   0.009   0.02
   + LA size                    0.775   0.08                0.346   0.02       0.008   0.02

Data were analyzed using area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI), and integrated discrimination improvement (IDI) with R software.

^a^Results of conventional risk factors (age, DM, hypertension, smoking) were taken as reference values for analyses.

LVDD: left ventricular diastolic dysfunction; LA: left atrium; ACS: acute coronary syndrome; AUC: area under the receiver operating characteristic curve; NRI: net reclassification improvement; IDI: integrated discrimination improvement.

DISCUSSION {#s3}
==========

Interest in CV outcomes after KT is increasing because CV disease is the leading cause of death and allograft loss in KT patients \[[@R14]\]. In this study of 2779 KT recipients, higher-grade LVDD was associated with more dilated LA, LV, and decreased LV systolic function. We also reported that pretransplant LVDD grades 2--3 and LAE were independently associated with a higher incidence of post-KT ACS, after multivariate analysis that adjusted for traditional risk factors.

The LVDD is frequently observed in ESRD patients. The association between LVDD and the occurrence of CAD had not been previously established in both CKD and normal renal function patients, although the association with heart failure and mortality had been established \[[@R15], [@R16]\]. A recent prospective cohort study reported that an increase in E/E' or LAVI was an independent risk factor for CV events in incident ESRD patients with preserved LV systolic function \[[@R17]\]. Unlike our study, the recent study included arrhythmia as well as coronary artery, cerebrovascular, and peripheral vascular disease in defining cardiovascular events. The study demonstrated that LVDD is closely related to the increase in LVMI and the association of LVDD with CAD by exemplifying several studies in which increased LVMI was associated with a higher incidence of CAD \[[@R17]\]. Our study also showed the marked increase of LVMI in LVDD grades 2--3 group than LVDD grades 0--1 group. Patients with LVDD were also known to have increased collagen levels in the myocardium \[[@R18]\]. This factor might be related to poor myocardial perfusion and increased CAD in patients with high-grade LVDD. Until now, there is little evidence to date of the association and mechanism of LVDD and CAD. This study is meaningful because it suggested that LVDD before transplantation is an independent factor in increasing post-transplant CAD occurrence.

LAE has been shown to indicate poor prognosis, not only in the general population \[[@R10], [@R19]\] but also in ESRD patients \[[@R5], [@R6], [@R20], [@R21]\], and KT recipients \[[@R7], [@R9]\]. In addition, it has been proposed that echocardiographic findings of LAE are useful markers of significant hemodynamic changes, which are in turn related to angiographically confirmed CAD \[[@R22]--[@R24]\]. LAE is a known manifestation of cardiac target-organ damage in the presence of established hypertension and increased LVM by enhancing cardiac oxygen demand and impairing LV filling and contractility \[[@R23], [@R24]\]. In our subgroup analysis, the patients who had both higher-grade LVDD and LAE had poorer CV outcomes than other patients. LAE has been suggested as a marker of LVDD severity and duration \[[@R10], [@R21]\], and it can lead to unfavorable outcomes related to irreversible functional or structural changes in the heart. Patients who were diagnosed with LAE without LVDD might have had atrial arrhythmia or mitral valve disease whose clinical implications are different.

In a multivariate analysis, neither higher-grade LVDD nor LAE before KT was significantly associated with post-KT all-cause mortality, although a previous study reported such an association \[[@R25]\]. The follow-up duration might have been too short to analyze mortality in this population. In addition, the mortality could have been affected by multifactorial components besides heart function, and the effect of LVDD and LAE might not have been sufficient to influence patient outcomes. Moreover, the parameters of LVDD and LAE are load-dependent and usually predict mortality mainly in patients with heart failure \[[@R26]\].

In another subgroup analysis, higher-grade LVDD in patients who underwent long term dialysis before KT showed poor CV outcomes, especially in patients with hemodialysis before KT. Volume overload pattern between hemodialysis and peritoneal dialysis is different and it varies Frank-Starling effects and the mechanism of worsening cardiac function over time \[[@R27],[@R28]\]. When patients show high-grade LVDD or LAE, especially those undergoing hemodialysis, more attention to improving those parameters should be considered.

To date, only few reports have examined the association between pre-KT echocardiographic findings and KT outcomes \[[@R6]--[@R9]\], and these were limited by small sample size. To the best of our knowledge, this study was conducted with the largest number of KT recipients to date. It is also notable for enrolling patients in two major transplantation centers in South Korea. We evaluated patients using relatively simple parameters that are easily measured with conventional transthoracic echocardiography. In addition, we defined CV outcomes as ACS, which is more specific to IHD and clear than "major adverse cardiac event".

Studies of CV disease frequently exclude chronic kidney disease or ESRD patients from enrollment. Our results are meaningful because we focused on ESRD patients who were awaiting KT and, after adjusting for all known risk factors, showed an independent association between easily determined echocardiographic findings (LVDD and LAE) before KT and CV disease outcomes after KT. To verify the consistency of our results, we conducted various statistical assessments of incremental predictive values.

This study has some limitations. First, it is a retrospective design, so LAVI was not routinely measured during echocardiography. LAVI is a more standardized method than linear LA size measurements for evaluating LA size in patients with a great variety of body sizes and should be preferred over linear dimensions \[[@R29]\]. Second, body habitus and gender are essential in categorizing LA size as normal or abnormal. To overcome these limitations, we evaluated the outcomes with LA size and/or LVDD, and divided the patients into four groups by LA size quartile. In addition, echocardiography was not performed at specific points between scheduled dialysis sessions, and there could have been significant differences in echocardiographic results before and after dialysis sessions. However, despite the limitations, our study could have significance per se because it would not be easy to perform randomized controlled studies with these subjects. Lastly, the population of this study was all Korean, so the results are not comparable with US or European cohorts. Korean KT recipients showed lower incidence of CV disease (including peripheral vascular disease, 2.4% at 5 year, and 11.4% at 12 year after KT) in former research \[[@R30]\], and the incidence of ACS in this study was also low. It might be because of low prevalence of DM, younger age, and/or ethnic disparity.

To further improve the outcomes of KT recipients, it is necessary to evaluate their modifiable risk factors associated with CV disease. Data from this study suggest that adverse CV outcomes may occur after KT in patients with pre-KT LVDD and LAE.

We have shown that the presence of higher-grade LVDD and LAE before KT is an independent predictor of posttransplant ACS. In addition, LVDD and LAE both showed significant superior discrimination power over traditional risk factors used to predict ACS. Further investigations are needed to assess whether improving those findings before KT would impact KT outcomes, and whether more active evaluation and treatment of CAD would be helpful for improving outcomes in these patients.

MATERIALS AND METHODS {#s4}
=====================

Study design and patients {#s4_1}
-------------------------

A total of 4650 patients who underwent KT at two major institutions for transplantation in South Korea (Seoul National University Hospital and Asan Medical Center) were screened. To evaluate the prognostic significance of pretransplant echocardiographic findings on outcomes in KT, researchers collected data from the 2779 adult recipients who had undergone pretransplant echocardiography from January 1997 to January 2012 and who had available data of LVDD or LA size. All patients were ≥ 15 years of age, and had pretransplant echocardiographic findings ≤ 1 year before KT. Basic clinical parameters were collected, such as age at the time of KT, sex, body mass index, comorbidities, dialysis modality/duration before KT, pretransplant echocardiographic findings and donor factors. This study was approved by the institutional review board (H-1409--086--609), and the need for informed consent was waived because this study used a retrospective design. All clinical investigations were conducted in accordance with the guidelines of the 2013 Declaration of Helsinki.

Definitions and grouping {#s4_2}
------------------------

LVDD was diagnosed according to the recommendations of the European Study Group on Diastolic Heart Failure \[[@R31]\] and divided into four grades on the basis of diastolic function using E/E' ratio, the E/A ratio, and the E wave deceleration time: 0 (normal); 1 (relaxation abnormality); 2 (pseudonormalization); and 3 (restrictive pattern) \[[@R32]\]. We divided the patients into two groups by LVDD grades: 0--1 vs. 2--3.

Meanwhile, patients were divided into four groups according to LA size quartiles: lowest quartile group is \< 36 mm (group 1), second quartile group is 36 mm ≤ LA size \< 40 mm (group 2), third quartile group is 40 mm ≤ LA size \< 44 mm (group 3), and largest quartile group is ≥ 44 mm (group 4).

For subgroup analysis, patients were divided into three groups by both LA size (median value of total study population: ≤ 38 mm or \> 38 mm) and LVDD groups (LVDD group 0--1 or 2--3).

LV systolic dysfunction was defined as ejection fraction \< 50%. The ACS was defined as universal definition of ST elevation myocardial infarction (MI), non-ST elevation MI, and unstable angina \[[@R33]\].

Primary and secondary objectives {#s4_3}
--------------------------------

The primary objective of this study was to evaluate whether pretransplant echocardiographic findings predicted the occurrence of ACS after KT. The secondary objective of this study was to evaluate all-cause mortality.

Statistical analysis {#s4_4}
--------------------

Most analyses were performed using IBM SPSS Statistics software v21.0 (IBM Corp., NY, USA). Continuous variables were expressed as the mean±standard deviation and were compared by using Student's *t*-test. For categorical variables, data were expressed as percentages and compared by using the Chi-square test. The Cox regression model was used to identify independent risk factors by calculating HR and 95% CI. Differences whose *P*-value was \< 0.05 were considered statistically significant. Using R version 3.2.0 (R Foundation for Statistical Computing, Wien, Austria), we evaluated the predictive contribution of LVDD or LA size to ACS risk using AUC, NRI, and IDI. ACS-free survival rates and other event-free survival rates were calculated using the Kaplan-Meier method, and group comparison was performed by using the log-rank test.
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The authors thank Nara Shin for her help in collecting the data.

**CONFLICTS OF INTEREST**

None declared.

**Authors' contributions**

All authors presented in this paper contributed extensively to the work at all stage. JHH collected data, analyzed the results, performed the study, and wrote the manuscript. JBP, YJK, JNA, CA, IMJ and CSL performed statistical analyses, interpreted the data analyses and revised the manuscript. YSK collected data, analyzed the results and revised the manuscript. YHK and JPL designed the study, analyzed the results, and wrote and edited the manuscript. All authors did final approval of the manuscript submitted. The results presented in this paper have not been published previously in whole or part, except in abstract form.

**FUNDING**

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number : HC15C1129).

ACS

:   acute coronary syndrome

AUC

:   area under the curve

CAD

:   coronary artery disease

CI

:   confidence interval

CV

:   cardiovascular

DM

:   diabetes mellitus

E/E'

:   E wave over tissue-Doppler imaging of the E wave

ESRD

:   end-stage renal disease

HR

:   hazard ratio

IDI

:   integrated discrimination improvement

KT

:   kidney transplant or kidney transplantation

LAE

:   left atrial enlargement

LAVI

:   left atrial volume index

LVDD

:   left ventricular diastolic dysfunction

LVH

:   left ventricular hypertrophy

LVMI

:   left ventricular mass index

NRI

:   net reclassification improvement

ROC

:   receiver operating characteristic

SD

:   standard deviation
